Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study

Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database

(2015) Morten O. Holmström et al.   AMERICAN JOURNAL OF HEMATOLOGY

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

(2015) R. Khan et al.   HAEMATOLOGICA

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

(2015) R. Khan et al.   HAEMATOLOGICA

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

(2014) M Merz et al.   LEUKEMIA

Classifying ultra-high risk smoldering myeloma

(2014) A J Waxman et al.   LEUKEMIA

Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials

(2014) Minjie Gao et al.   PLoS One

Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load

(2013) Kai Neben et al.   JOURNAL OF CLINICAL ONCOLOGY

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

(2013) Benjamin M. Cherry et al.   LEUKEMIA & LYMPHOMA

Treatment for High-Risk Smoldering Myeloma

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

(2012) J T Larsen et al.   LEUKEMIA

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

(2012) E Kastritis et al.   LEUKEMIA

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD